Catherine Sabatos-Peyton
Chief Executive Officer Larkspur Biosciences
Seminars
Tuesday 27th October 2026
Panel Discussion: Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact
9:00 am
- Examining recent advances across degrader and non-degrader modalities, highlighting how new discoveries are moving the field beyond oncology
- Assessing the influence of global markets, including China, on drug development, the clinical landscape and strategic collaborations in induced proximity therapeutics
- Identifying emerging opportunities, bottlenecks, and the next frontiers in translating platform innovations into clinically relevant therapies
Tuesday 27th October 2026
Targeting Cancer Fitness: PIP4K2C Degrader LRK-4189 Enters the Clinic for MSS CRC & Beyond
11:00 am
- Developing first-in-class cereblon-based heterobifunctional degraders that target cancer fitness, the stress adaptations cancer cells use to proliferate, invade tissue, and escape immune detection
- Our FIH study of LRK-4189 was a single-ascending dose study in healthy volunteers, a strategic approach to rapidly identifying a pharmacologically active dose
- Emergent data support progression of LRK-4189 in MSS CRC through characterization of the tumor genetics and molecular pathways that drive dependency on PIP4K2C
